Evidence map›Paper›PMID 35222016›Full record

ArticleFrontiers in pharmacology2022

Verification of the Usefulness of an Assessment and Risk Control Sheet that Promotes Management of Cancer Drug Therapy.

O Honma, C Watanabe, H Fukuchimoto, J Kashiwazaki, M Tateba, S Wagatsuma, K Ogata, K Maki, H Sonou, K Shiga and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 1 country.

O HonmaDepartment of Nursing, Showa University Hospital, Tokyo, Japan.
C WatanabeDepartment of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Kanagawa, Japan.
H FukuchimotoDepartment of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Kanagawa, Japan.
J KashiwazakiFaculty of Nursing, Kyoritsu Women's University, Tokyo, Japan.
M TatebaDepartment of Nursing, Showa University Hospital, Tokyo, Japan.
S WagatsumaDepartment of Nursing, Showa University Hospital, Tokyo, Japan.
K OgataDepartment of Nursing, Showa University Hospital, Tokyo, Japan.
K MakiDepartment of Nursing, Showa University Hospital, Tokyo, Japan.
H SonouDepartment of Nursing, Showa University Hospital, Tokyo, Japan.
K ShigaDepartment of Nursing, Showa University Koto Toyosu Hospital, Tokyo, Japan.
E OtsukaDepartment of Nursing, Showa University Hospital, Tokyo, Japan.
M HirutaDepartment of Nursing, Showa University Hospital, Tokyo, Japan.
Y HirasawaDepartment of Medical Oncology, Showa University, Tokyo, Japan.
M HosonumaDepartment of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
M MurayamaDepartment of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
Y NarikawaDepartment of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
H ToyodaDepartment of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
T TsuruiDepartment of Medical Oncology, Showa University, Tokyo, Japan.
A KuramasuDepartment of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
M KinDepartment of Pharmacy, Showa University Hospital, Tokyo, Japan.
Y KubotaDepartment of Medical Oncology, Showa University, Tokyo, Japan.
T SambeDivision of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Shinagawa-ku, Japan.
A HoriikeDepartment of Medical Oncology, Showa University, Tokyo, Japan.
H IshidaDivision of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
K ShimadaDivision of Medical Oncology, Internal Medicine Center, Showa University Koto Toyosu Hospital, Tokyo, Japan.
M UmedaFamily Hospice Co., Ltd., Tokyo, Japan.
T TsunodaDepartment of Medical Oncology, Showa University, Tokyo, Japan.
K YoshimuraDepartment of Clinical Immunology and Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
Showa University · JPShowa University Hospital · JPKoto Hospital · JPKyoritsu Women's University · JPShowa University Northern Yokohama Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adverse eventassessmentcommon terminology criteria for adverse eventsdrug therapynursingpre-examination

Identifiers

PMID35222016
PMCPMC8864067
OpenAlexW4211082743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.